Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors at 7 institutions in 1 country.
Masahiro OuraDepartment of Hematology Endocrinology and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.ORCID https://orcid.org/0009-0008-0260-8171
Takeshi HaradaDepartment of Hematology Endocrinology and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.ORCID https://orcid.org/0000-0002-3997-7471
Asuka OdaDepartment of Hematology Endocrinology and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
Jumpei TeramachiDepartment of Oral Function and Anatomy Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama University Okayama Japan.
Shingen NakamuraDepartment of Community Medicine and Medical Science Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.ORCID https://orcid.org/0000-0001-5465-2758
Masafumi NakamuraDepartment of Internal Medicine Tokushima Prefecture Naruto Hospital Tokushima Japan.
Tomoyo HaraDepartment of Hematology Endocrinology and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
Hiroki YamagamiDepartment of Hematology Endocrinology and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
Kiyoe KurahashiDepartment of Community Medicine for Respirology Hematology and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
Itsuro EndoDepartment of Bioregulatory Sciences Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
Hiroo HasegawaDepartment of Laboratory Medicine Nagasaki University Hospital Nagasaki Japan.
Hiroshi FujiwaraDepartment of Personalized Cancer Immunotherapy Mie University Graduate School of Medicine Mie Japan.
Masahiro AbeDepartment of Hematology Endocrinology and Metabolism Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
Tokushima University · JPTokushima University Hospital · JPMie University · JPNagasaki University Hospital · JPNaruto, Tokushima Prefecture hospital · JPOkayama University · JPOsaka Metropolitan University · JP
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Adult T-cell leukaemia/lymphoma (ATL) remains incurable. The NF-κB and interferon regulatory factor 4 (IRF4) signalling pathways are among the critical survival pathways for the progression of ATL. TGF-β-activated kinase 1 (TAK1), an IκB kinase-activating kinase, triggers the activation of NF-κB. The resorcylic acid lactone LL-Z1640-2 is a potent irreversible inhibitor of TAK1/extracellular signal-regulated kinase 2 (ERK2). We herein examined the therapeutic efficacy of LL-Z1640-2 against ATL. LL-Z1640-2 effectively suppressed the in vivo growth of ATL cells. It induced in vitro apoptosis and inhibited the nuclear translocation of p65/RelA in ATL cells. The knockdown of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Therapeutic efficacy of the resorcylic acid lactone LL-Z1640-2 for adult T-cell leukaemia/lymphoma. · full record | OpenQuestion